Aptamers: a promising chemical antibody for cancer therapy


Autoria(s): Zhou, Gang; Wilson, George; Hebbard, Lionel; Duan, Wei; Liddle, Christopher; George, Jacob; Qiao, Liang
Data(s)

01/01/2016

Resumo

Aptamers, also known as chemical antibodies, are single-stranded nucleic acid oligonucleotides which bind to their targets with high specificity and affinity. They are typically selected by repetitive in vitro process termed systematic evolution of ligands by exponential enrichment (SELEX). Owing to their excellent properties compared to conventional antibodies, notably their smaller physical size and lower immunogenicity and toxicity, aptamers have recently emerged as a new class of agents to deliver therapeutic drugs to cancer cells by targeting specific cancer-associated hallmarks. Aptamers can also be structurally modified to make them more flexible in order to conjugate other agents such as nano-materials and therapeutic RNA agents, thus extending their applications for cancer therapy. This review presents the current knowledge on the practical applications of aptamers in the treatment of a variety of cancers.

Identificador

http://hdl.handle.net/10536/DRO/DU:30082603

Idioma(s)

eng

Publicador

Impact Journals

Relação

http://dro.deakin.edu.au/eserv/DU:30082603/duan-aptamersapromising-2016.pdf

http://www.dx.doi.org/10.18632/oncotarget.7178

Direitos

2016, Impact Journals LLC

Palavras-Chave #SELEX #aptamers #cancers #siRNA #target therapy #Science & Technology #Life Sciences & Biomedicine #Oncology #Cell Biology #TARGETED DRUG-DELIVERY #GROWTH-FACTOR RECEPTOR #RENAL-CELL CARCINOMA #RNA APTAMER #IN-VIVO #TUMOR-CELLS #DNA-APTAMER #HIGH-AFFINITY #OLIGONUCLEOTIDE APTAMERS #4-1BB COSTIMULATION
Tipo

Journal Article